Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Brown

Urogynecology and Reconstructive Pelvic Surgery Mobile, AL Medical Doctor

NPI 1932223526 CMS profile 87989

168 Mobile Infirmary Blvd, Mobile, AL 36607

Open in the dashboard

General payments

$8,305

294 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$89,364 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Robert Brown of Mobile, AL is reported in the CMS Open Payments database as having received $8,305 across 294 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $89,364 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 75th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,342 64
2024 General $1,052 41
2023 General $874 34
2022 General $900 34
2021 General $882 35
2020 General $653 30
2019 General $2,602 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Brown
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Robert Brown were reported at $1,342. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Robert Brown Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $2,602 $358 $132–$1,270 $163
2020 $653 $198 $86–$642 $114
2021 $882 $361 $118–$1,182 $132
2022 $900 $410 $128–$1,175 $149
2023 $874 $434 $152–$1,344 $160
2024 $1,052 $494 $193–$1,331 $164
2025 $1,342 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Axonics Modulation Technologies, Inc. $1,861 45 payments
  2. Intuitive Surgical, Inc. $1,767 6 payments
  3. AbbVie, Inc. $1,002 54 payments
  4. Astellas Pharma US Inc $543 23 payments
  5. Boston Scientific Corporation $481 12 payments
  6. Sumitomo Pharma America, Inc. $455 26 payments
  7. TherapeuticsMD, Inc. $269 18 payments
  8. Pfizer Inc. $252 20 payments
  9. Coloplast Corp $227 17 payments
  10. Allergan Inc. $128 9 payments
  11. Other $1,320 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,311 284 payments
  2. Education $1,011 6 payments
  3. Travel and Lodging $982 4 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $1,767 6 payments
  2. Axonics $1,340 26 payments
  3. BOTOX Botox Therapeutic $541 31 payments
  4. Axonics r-SNM System Urology $486 16 payments
  5. GEMTESA $478 27 payments
  6. Axonics r-SNM System Urology $352 10 payments
  7. PREMARIN $301 23 payments
  8. MYRBETRIQ $281 19 payments
  9. Orilissa $236 7 payments
  10. BOTOX Urology $178 13 payments
  11. Other $2,421 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

747

Median for Obstetrics & Gynecology: 65

Drug cost

$196,740

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

61.8%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 115 $93,483
Myrbetriq Mirabegron Brand 91 $72,785
Premarin Estrogens, Conjugated Brand 45 $18,722
Estradiol Generic 99 $4,513
Estradiol (Twice Weekly) Estradiol Brand 16 $2,082
Estradiol (Once Weekly) Estradiol Brand 12 $1,479
Oxybutynin Chloride Er Oxybutynin Chloride Brand 63 $968
Fluconazole Generic 100 $964
Nystatin-Triamcinolone Nystatin/Triamcinolone Acet Brand 28 $625
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 31 $362

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$218,800

Medicare's payments for the services billed

Medicare patients

333

Average age 75

Services billed

3,502

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 71%
Ischemic heart disease 31%
Depression 30%
Osteoporosis 29%
Diabetes 28%
Chronic kidney disease 25%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $321
$321 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $104
$104 115 —
ORGOVYX
  • Sumitomo Pharma America, Inc. $29
$29 — —
FEMRING
  • MILLICENT US INC $17
$17 — —
INTRAROSA
  • MILLICENT US INC $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

294 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record